ArticleEuropean urology2023
Re: Toni K. Choueiri, Thomas Powles, Laurence Albiges, et al. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med 2023;388:1767-78.
Clara Cerrato et al.PubMed ↗Publisher ↗
No numbers read from the abstract.